Citigroup Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Biogen (NASDAQ:BIIB) had its price target raised by equities research analysts at Citigroup from $185.00 to $215.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Citigroup’s target price would indicate a potential upside of 9.81% from the stock’s current price.

Other analysts have also issued research reports about the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $225.00 target price on shares of Biogen in a report on Thursday, January 8th. Wedbush increased their price target on shares of Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a report on Monday. Morgan Stanley set a $190.00 price objective on shares of Biogen in a research report on Sunday. Truist Financial lifted their target price on Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a research report on Monday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a report on Monday. Thirteen equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $205.30.

Biogen Stock Performance

Shares of Biogen stock traded down $5.40 on Monday, reaching $195.79. The stock had a trading volume of 610,366 shares, compared to its average volume of 1,640,478. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The business’s 50-day moving average price is $176.94 and its two-hundred day moving average price is $157.05. The stock has a market cap of $28.72 billion, a P/E ratio of 22.21, a price-to-earnings-growth ratio of 1.70 and a beta of 0.16. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter last year, the firm posted $3.44 EPS. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, sell-side analysts forecast that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 748 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Large investors have recently made changes to their positions in the company. Empowered Funds LLC boosted its position in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after buying an additional 2,777 shares in the last quarter. Focus Partners Wealth boosted its holdings in shares of Biogen by 172.2% in the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Biogen during the 2nd quarter valued at $216,000. Blair William & Co. IL raised its position in Biogen by 11.8% in the 2nd quarter. Blair William & Co. IL now owns 14,844 shares of the biotechnology company’s stock valued at $1,864,000 after purchasing an additional 1,561 shares during the last quarter. Finally, Callan Family Office LLC acquired a new position in Biogen in the second quarter worth $308,000. Institutional investors own 87.93% of the company’s stock.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance — Biogen reported Q4 EPS and revenue above estimates and set FY2026 EPS guidance well above Street expectations, driving investor optimism about near-term profitability and demonstrating stabilization after recent headwinds. Biogen Posts Q4 Beat, Analysts Raise Price Targets On ‘Significant Pipeline Diversification’
• Positive Sentiment: Analyst upgrades / higher targets — Several firms (RBC, HC Wainwright, others) raised price targets and reiterated buys/outperform ratings after the print, signaling dealer confidence in upside tied to LEQEMBI traction and cash flow. RBC Raises Price Target on Biogen to $233 From $217
• Positive Sentiment: Regulatory progress for LEQEMBI — The biologics license application for a subcutaneous formulation of LEQEMBI has been designated for priority review, which could expand the drug’s market and ease administration logistics if approved. Biologics License Application for Subcutaneous Formulation of “LEQEMBI” Designated for Priority Review
• Positive Sentiment: Commercial momentum — Reports show LEQEMBI sales jumped and the stock hit a 52‑week high on the strength of Alzheimer’s drug demand, supporting the thesis that new revenue streams are offsetting declines elsewhere. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Neutral Sentiment: Mixed analyst stance — Several firms raised price targets but kept neutral/hold ratings (Piper Sandler, Wedbush, Truist, Morgan Stanley, UBS), reflecting disagreement on sustainable growth and execution risk despite the beat. Piper Sandler Raises Price Target
• Negative Sentiment: MS franchise pressure — Core multiple sclerosis product sales declined and were cited on the call and in coverage as a continuing drag on revenue; investors may worry about duration and magnitude of that erosion. Biogen Revenue Down as Multiple Sclerosis Sales Slide (WSJ)
• Negative Sentiment: Execution and growth risk flagged by analysts — Deeper-dive commentary (Seeking Alpha and others) highlights MS weakness and the high-risk nature of pipeline bets, which could cap valuation if LEQEMBI uptake or new approvals slow. Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.